Home / Health / Hormone Therapy Boosts Weight Loss Drug Efficacy
Hormone Therapy Boosts Weight Loss Drug Efficacy
31 Mar
Summary
- Combining hormone therapy with tirzepatide increased weight loss.
- Women on both lost 19.2% body weight vs. 14% on drug alone.
- Further trials are planned to confirm benefits and heart health.
The menopause transition is often associated with increased risk of obesity. A recent study indicates that combining menopausal hormone therapy with tirzepatide, a popular weight-loss medication, may offer improved results for women experiencing weight gain during midlife.
Researchers analyzed data from 120 women, primarily in their 50s, who were using tirzepatide. A subset of these women also utilized menopausal hormone therapy. The findings revealed that participants using both treatments achieved an average weight loss of 19.2 percent, substantially more than the 14 percent average weight loss observed in those using tirzepatide only.
This enhanced weight loss with the drug combination suggests a significant interaction that warrants further investigation. While the precise mechanisms remain unclear, potential factors include healthier habits among hormone therapy users or improved adherence to lifestyle changes due to symptom relief. Researchers plan a controlled trial to validate these findings and explore broader health benefits. The research, published in The Lancet Obstetrics, Gynaecology, and Women's Health, did not differentiate between hormone therapy types, a noted limitation. Future studies aim to confirm these results and assess impacts on cardiovascular and metabolic health.
